Immunologic Response to Secukinumab in Plaque Psoriasis

Phase 4

Completed

• Conditions: Psoriasis
• Interventions: Drug: Secukinumab

• Registration Number: NCT02592018
• Lead Sponsor: University of California, San Francisco

Brief Summary

This is a single-arm, open-label study, which will examine the effect of secukinumab on the immunologic and genetic environment within psoriatic lesions.

Detailed Description

Quantitative analysis of the immunologic changes in immune cell populations will be performed after secukinumab treatment in 15 patients at weeks 2, 4, and 12 compared to baseline week 0. The immunologic profiles in psoriasis patients will also be compared to healthy control skin surgical discard specimens (n=10). The number of differentially expressed genes in each cell population will be quantified by RNA-seq at weeks 2, 4, 12 after secukinumab compared to baseline.

Study Timeline

• Study First Submitted: 2015-10-16
• Study First Submitted QC: 2015-10-28
• Study First Posted: 2015-10-30
• Study Start: 2016-10
• Primary Completion: 2018-12
• Study Completion: 2018-12
• Results First Submitted: 2020-06-23
• Status Verified: 2020-08
• Results First Submitted QC: 2020-08-12
• Results First Posted: 2020-08-27
• Last Update Submitted: 2020-08-31
• Last Update Posted: 2020-09-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. Ability to provide written informed consent and comply with the protocol.
2. At least 18 years of age.
3. Diagnosis of predominately plaque psoriasis for at least 6 months prior to enrollment.
4. Subject is considered a candidate for phototherapy or systemic therapy
5. PASI ≥ 12
6. PGA ≥ 3
7. Subject has a negative Quantiferon Gold, or if positive undergoes CXR. If CXR negative, subject initiated prophylactic therapy with isoniazid for a course of 9 months with one month of therapy completed prior to first dose of secukinumab.
8. Subject is unlikely to conceive (male, post-menopausal, or using adequate oral contraceptive therapy or IUD).
9. Physical exam within clinically acceptable limits.

Exclusion Criteria

1. Subject is unable to provide written informed consent or comply with the protocol.
2. Subject is younger than 18 years of age.
3. Subject has predominately non-plaque form of psoriasis.
4. Subject with mild psoriasis (PASI<12 and PGA<3) or is not a candidate for phototherapy or systemic treatments.
5. Subject has drug-induced psoriasis.
6. Subject with current, or a history of, severe psoriatic arthritis well controlled on current therapy.
7. Subjects with a serum creatinine level exceeding 176.8 μmol/L (2.0 mg/dl).
8. Screening total white blood cell (WBC count) < 2,500/μl, platelets < 100,000/μl, neutrophils < 1,500/μl, or hemoglobin <8.5 g/dl.
9. Evidence of active tuberculosis infection as defined by a positive QuantiFERON TB-Gold test (QFT) with a positive chest X-ray at screening, or untreated latent tuberculosis defined by positive QFT with a negative chest X-ray without prophylactic therapy with isoniazid for a course of 9 months with one month of therapy completed prior to first dose of secukinumab.
10. History of an ongoing, chronic or recurrent infectious disease including past medical history record of HIV, hepatitis B or hepatitis C.
11. Subjects possess other diagnoses that, in the investigator's opinion, preclude him/her from safely participating in this study or interfere with the evaluation of the subject's psoriasis.
12. History of known or suspected intolerance to any of the ingredients of the investigational study product.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Secukinumab	Secukinumab	All subjects will receive Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48.

Primary Outcome Measures

Name	Time	Method
Change in Percentage of CD4+ T Effector Cells Expressing IL17 Compared to Baseline	Baseline to Week 12

Secondary Outcome Measures

Name	Time	Method
Change in Number of Differentially Expressed Genes in CD4+ T Regs Compared to Baseline	Baseline to Week 12	by RNA-seq
Change in Number of Differentially Expressed Genes in CD8+ T Effectors Compared to Baseline	Baseline to Week 12	by RNA-seq
Change in Number of Differentially Expressed Genes in CD4+ Effectors Compared to Baseline Across All Participants	Baseline to Week 2	by RNA-seq
Change in Number of Differentially Expressed Genes in CD4+ Effectors Compared to Baseline	Baseline to Week 12	by RNA-seq

Trial Locations

Locations (1)

UCSF Psoriasis and Skin Treatment Center; 🇺🇸 San Francisco, California, United States